Lentinan combined radiofrequency ablation and transcatheter arterial chemoembolization for hepatocellular carcinoma

Take 82 liver cancer patients confirmed by pathology and diagnostic imaging into this research project. 165 tumors whose average diameter of 6.5 cm (standard deviation [SD] ± 0.7) have been detected. Then the patients were divided into four groups and received four different medical treatments for each group, which are radiofrequency ablation, transcatheter hepatic arterial chemoembolization, the combination group+lentinan treatment and RFA and TACE treatment. The combination of therapies, such as lentinan, RFA and TACE treatment is more effective in extending the average survival time, increasing tumor necrosis and reducing the relapse rate than traditional treatments. Therefore, lentinan may be beneficial for patients with hepatocellular carcinoma.